EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using 18 FDG and 64 Cu-DOTA-Trastuzumab Positron Emission Tomography Studies

John Whitman iD, Vikram Adhikarla, Lusine Tumyan, Joanne Mortimer iD, Wei Huang, Russell Rockne iD, Joesph R Peterson iD, John Cole

JCO Clinical Cancer Informatics · 2025-01 · (9)

DOI: 10.1200/cci.23.00248 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift JCO Clinical Cancer Informatics, 2025-01. Verfasst von John Whitman und 7 weiteren Autor:innen. Beteiligte Einrichtung: SimBioSys Inc, Chicago, IL. Hauptthemen laut MEDLINE: Breast Neoplasms, Magnetic Resonance Imaging, Positron-Emission Tomography, Trastuzumab. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Perfusion modeling presents significant opportunities for imaging biomarker development in breast cancer but has historically been held back by the need for data beyond the clinical standard of care (SoC) and uncertainty in the interpretability of results. We aimed to design a perfusion model applicable to breast cancer SoC dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) series with results stable to low temporal resolution imaging, comparable with published results using full-resolution DCE-MRI, and correlative with orthogonal imaging modalities indicative of biophysical markers. METHODS Subsampled high-temporal-resolution DCE-MRI series were run through our perfusion model and resulting fits were compared for consistency. The fits were also compared against previously published results from institutions using the full resolution series. The model was then evaluated on a separate cohort for validity of biomarker indications. Finally, the model was used as a fundamental part of predicting response to neoadjuvant chemotherapy (NACT). RESULTS Temporally subsampled DCE-MRI series yield perfusion fit variations on the scale of 1% of the tumor median value when input frames are varied. Fits generated from pseudoclinical series are within the variation range seen between imaging sites (ρ = 0.55), voxel-wise. The model also demonstrates significant correlations with orthogonal positron emission tomography imaging, indicating potential for use as a biomarker proxy. Specifically, using the perfusion fits as the grounding for a biophysical simulation of response, we correctly predict the pathologic complete response status after NACT in 15 of 18 patients, for an accuracy of 0.83, with a specificity and sensitivity of 0.83 as well. CONCLUSION Clinical DCE-MRI data may be leveraged to provide stable perfusion fit results and indirectly interrogate the tumor microenvironment. These fits can then be used downstream for prediction of response to NACT with high accuracy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMagnetic Resonance ImagingPositron-Emission TomographyTrastuzumabFluorodeoxyglucose F18HumansFemaleNeoadjuvant TherapyContrast MediaMiddle AgedOrganometallic CompoundsAdultAgedRadiopharmaceuticals

Substanzen

TrastuzumabContrast MediaFluorodeoxyglucose F18Organometallic CompoundsRadiopharmaceuticals

Autor:innen und Institutionen

  • SimBioSys Inc, Chicago, IL.
  • Division of Mathematical Oncology and Computational Systems Biology, Beckman Research Institute, City of Hope, Duarte, CA.
  • Department of Radiology, City of Hope National Medical Center, Duarte, CA.
  • Department of Medical Oncology and Medical Therapeutics Research, City of Hope National Medical Center, Duarte, CA.
  • Advanced Imaging Research Center, Oregon Health and Science University, Portland, OR.
  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR.

ORCID-Profile: John Whitman, Joanne Mortimer, Russell Rockne, Joesph R Peterson

Förderung

  • NCI NIH HHS

Zitieren

APA

Whitman, J., Adhikarla, V., Tumyan, L., Mortimer, J., Huang, W., Rockne, R., Peterson, J. R., & Cole, J. (2025). Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using 18 FDG and 64 Cu-DOTA-Trastuzumab Positron Emission Tomography Studies. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.23.00248

Vancouver

Whitman J, Adhikarla V, Tumyan L, Mortimer J, Huang W, Rockne R, et al. Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using 18 FDG and 64 Cu-DOTA-Trastuzumab Positron Emission Tomography Studies. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci.23.00248

BibTeX
@article{Whitman2025,
  author = {Whitman, John and Adhikarla, Vikram and Tumyan, Lusine and Mortimer, Joanne and Huang, Wei and Rockne, Russell and Peterson, Joesph R and Cole, John},
  title = {Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using 18 FDG and 64 Cu-DOTA-Trastuzumab Positron Emission Tomography Studies},
  journal = {JCO Clinical Cancer Informatics},
  year = {2025},
  number = {9},
  doi = {10.1200/cci.23.00248}
}
Kostenlos starten →